Asset Details
Do you wish to reserve the book?
Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination
Do you wish to request the book?
Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination
2025
Overview
The safety profile of COVID-19 vaccines is well-established, yet the widespread immunization campaign has led to an increase in reported cases of Immune-Mediated and Rheumatic Diseases (IMDRs). This study aimed to assess the reporting of Adverse Events Following Immunization (AEFIs) related to IMDRs after COVID-19 vaccination. We analyzed all individual case safety reports (ICSRs) related to COVID-19 vaccines authorized in the European Union (i.e., tozinameran, elasomeran, ChAdOx1-S NCoV-19, and Ad26.Cov2.S) registered in the EudraVigilance (EV) database from January 1, 2021, to October 23, 2023. Our analysis identified ICSRs with events indicative of IMDRs and conducted disproportionality analysis (i.e., Reporting Odds Ratio (ROR) with 95% CI) to examine the frequency of different IMDR types linked to each vaccine. In total, 45,352 ICSRs reported at least one AEFI associated with rheumatic or autoimmune conditions, with 54% of them implicating tozinameran as the suspected vaccine. More than half of the reported AEFIs were classified as serious, with approximately 45% remaining unresolved. The most frequently reported conditions were other immune-mediated diseases, followed by arthritis, vasculitis, systemic lupus erythematosus, and tendinopathies. Our disproportionality analysis suggested that mRNA vaccines may be more frequently associated with new autoimmune rheumatic diseases. Stratified analysis revealed significant associations for ChAd, particularly in vasculitis and tendinopathies, only when compared to Ad26.Cov2.S. Real-world pharmacovigilance data suggest that autoimmune and rheumatic diseases may be under-reported following COVID-19 vaccination, highlighting the need for further research to better understand the underlying mechanisms. The findings from this disproportionality analysis suggest the need for further studies to investigate these results in greater depth.
Publisher
Nature Publishing Group UK,Nature Portfolio
Subject
/ 692/4023
/ 692/499
/ 692/700
/ Adult
/ Adverse Drug Reaction Reporting Systems
/ Aged
/ Autoimmune Diseases - epidemiology
/ Autoimmune Diseases - etiology
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - adverse effects
/ Female
/ Humanities and Social Sciences
/ Humans
/ Male
/ Rheumatic Diseases - epidemiology
/ Rheumatic Diseases - etiology
/ Safety
/ Science
/ Vaccination - adverse effects
/ Vaccines
